Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study

Chyke Doubeni, University of Pennsylvania
Douglas A. Corley, Kaiser Permanente Northern California
Virginia P. Quinn, Kaiser Permanente Southern California
Christopher D. Jensen, Kaiser Permanente Northern California
Ann G. Zauber, Memorial Sloan Kettering Cancer Center
Michael Goodman, Emory University
Jill R. Johnson, University of Pennsylvania
Shivan J. Mehta, University of Pennsylvania
Tracy A. Becerra, Kaiser Permanente Southern California
Wei K. Zhao, Kaiser Permanente Northern California

Only first 10 authors above; see publication for full author list.

Journal Title: Gut
Volume: Volume 67, Number 2
Publisher: BMJ Publishing Group | 2018-02-01, Pages 291-U253
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1136/gutjnl-2016-312712
Permanent URL: https://pid.emory.edu/ark:/25593/s8rfd

Final published version: http://dx.doi.org/10.1136/gutjnl-2016-312712

Copyright information:
© 2016 BMJ Publishing Group Ltd & British Society of Gastroenterology. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).

Accessed March 3, 2020 4:18 AM EST
Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study

Chyke A Doubeni,1 Douglas A Corley,2 Virginia P Quinn,3 Christopher D Jensen,2 Ann G Zauber,4 Michael Goodman,5 Jill R Johnson,1 Shivan J Mehta,6 Tracy A Becerra,3 Wei K Zhao,2 Joanne Schottinger,3 V Paul Doria-Rose,7 Theodore R Levin,2 Noel S Weiss,8 Robert H Fletcher9

ABSTRACT
Objective Screening colonoscopy’s effectiveness in reducing colorectal cancer mortality risk in community populations is unclear, particularly for right-colon cancers, leading to recommendations against its use for screening in some countries. This study aimed to determine whether, among average-risk people, receipt of screening colonoscopy reduces the risk of dying from both right-colon and left-colon/rectal cancers.

Design We conducted a nested case–control study with incidence-density matching in screening-eligible Kaiser Permanente members. Patients who were 55–90 years old on their colorectal cancer death date during 2006–2012 were matched on diagnosis (reference) date to controls on age, sex, health plan enrolment duration and geographical region. We excluded patients at increased colorectal cancer risk, or with prior colorectal cancer diagnosis or colectomy. The association between screening colonoscopy receipt in the 10-year period before the reference date and colorectal cancer death risk was evaluated while accounting for other screening exposures.

Results We analysed 1747 patients who died from colorectal cancer and 3460 colorectal cancer-free controls. Compared with no endoscopic screening, receipt of a screening colonoscopy was associated with a 67% reduction in the risk of death from any colorectal cancer (adjusted OR (aOR)=0.33, 95% CI 0.21 to 0.52). By cancer location, screening colonoscopy was associated with a 65% reduction in risk of death for right-colon cancers (aOR=0.35, CI 0.18 to 0.65) and a 75% reduction for left-colon/rectal cancers (aOR=0.25, CI 0.12 to 0.53).

Conclusions Screening colonoscopy was associated with a substantial and comparably decreased mortality risk for both right-sided and left-sided cancers within a large community-based population.

INTRODUCTION
Colorectal cancer is a leading cause of cancer deaths worldwide.1–2 Evidence from multiple randomised trials has established that screening with either faecal occult blood tests (FOBTs)3–5 or sigmoidoscopy6–9 can reduce colorectal cancer incidence and death. However, evidence of the ability of screening to substantially reduce risk for right-colon disease is limited. Although colonoscopy is the most commonly used colorectal cancer screening test in the USA,10–12 its effectiveness is not yet supported by evidence from randomised trials.13–17 Some studies have also questioned colonoscopy’s effectiveness for cancers in the right colon, but many previous studies had methodological limitations such as the inability to know which tests were for screening or for diagnostic purposes.

What is already known on this subject?
► Screening is effective at reducing the risk of death from colorectal cancer.
► There is only limited evidence in the ability of currently available tests to substantially reduce the risk of death from right colon cancers.
► Some studies have questioned colonoscopy’s effectiveness for cancers in the right colon, but many previous studies had methodological limitations such as the inability to know which tests were for screening or for diagnostic purposes.

What are the new findings?
► Screening colonoscopy use was associated with a 65% reduction in risk of death in the right colon and a 75% reduction in risk of death for left-colon/rectal cancers.
► The effectiveness of screening colonoscopy in the right colon was not significantly different from that in the left colon/rectum.

How might it impact on clinical practice in the foreseeable future?
► The current study supports colonoscopy as an effective screening test for reducing mortality from both left-sided and right-sided colon cancers.
► The results should help allay concerns that colonoscopy could be substantially less effective in the right than the left colon/rectum or less effective in real-world community-based populations.
randomised trials. Few observational studies have examined the effectiveness of colonoscopy, separately, in the right and left colon/rectum, and results have been mixed. Early studies found little or no effectiveness in the right colon, raising the possibility that clinically important lesions in the right colon are either biologically different and/or less readily detectable by colonoscopy. However, those studies used administrative data and thus were unable to distinguish screening colonoscopies from those performed for symptoms or account for confounding. More recent studies found some evidence of effectiveness in the right colon, but with wide CIs and design limitations, including the use of self-reported screening exposure and the use of cancer stage instead of mortality as an endpoint. Rational screening policy depends on knowing the presence of and possible magnitude of screening colonoscopy’s effectiveness in the right and left colon to justify the added inconvenience, risk and cost of colonoscopy, particularly relative to sigmoidoscopy. The Canadian Task Force on Preventive Health Care recently recommended against using colonoscopy as a screening test for colorectal cancer, citing the low quality of evidence on its use.

We conducted a study in members of two large community-based integrated health systems to examine the extent to which screening colonoscopy use reduced the risk of death from colorectal cancer overall, and in the right colon, an area of continuing uncertainty. We also evaluated the association between screening colonoscopy use and the risk of death from colorectal cancer in ≥1 first-degree relatives before age 50, or ≥2 first-degree or second-degree relatives at any age; or familial colorectal cancer syndromes. We also excluded those who had GI cancer or colectomy before the reference date.

Case patient ascertainment and control selection
Given colonoscopy may decrease the risk of death from colorectal cancer for an extended period after its performance, and several years may elapse between screening events, cancer diagnosis and death, we selected as cases men or women who were 55–90 years old on the date of death from colorectal adenocarcinoma as the underlying cause during 2006–2012. Vital status and the cause of death were obtained from state mortality files. Cancer diagnosis date and tumour characteristics (histology, stage and location) were obtained from the health plans’ Surveillance, Epidemiology and End Results Programme-affiliated tumour registries. Tumours located proximal to the splenic flexure were categorised as ‘right-colon’, others as ‘left-colon/rectum’ or ‘ unspecified.’

Each case patient was individually matched to controls using an incidence-density matching approach on the reference date on birth year (±1 year), sex, the duration of health plan enrolment prior to diagnosis (±1 year) and the geographical region in each health plan where the majority of patients’ care was received. The use of incidence-density matching in a dynamic population that could be tracked longitudinally along with matching on geographical location helped reduce socioeconomic variation between cases and controls and thus minimised selection bias. Eight controls were initially identified for each case, with a goal of completing chart audits on two randomly selected eligible controls per case.

Screening colonoscopy exposures
We ascertained receipt of colonoscopy, sigmoidoscopy, CT colonography and/or FOBT in the 10-year period before the reference date (observation period), including tests that detected the index cancer. Test indication was determined in a multistep process as described previously (see online supplementary technical appendix). Briefly, trained auditors collected the dates, findings and reasons for all relevant tests from progress, referral and endoscopy procedure notes in medical records. This approach allowed us to integrate information from the primary care or referring provider and the endoscopist with information on laboratory and imaging studies to assign test indication. We then used a previously developed algorithm to classify each test’s indication into mutually exclusive categories: definite-screening, probable-screening, surveillance, possible-diagnostic, probable-diagnostic, definite-diagnostic or unknown (see online supplementary table S1). Tests were classified as probable-screening if both screening and non-specific abdominal symptoms such as diarrhoea were recorded as reasons for performing it. The indication was definite-screening if screening alone and no colorectal cancer-related conditions were recorded (see online supplementary technical appendix).

A colonoscopy was classified as surveillance if performed for follow-up of previously detected polyps; ‘definite’ diagnostic if used to work-up a positive FOBT, abnormal sigmoidoscopy, a mass or other abnormal finding such as on imaging; ‘probable’ diagnostic if the medical records noted clinical conditions that were deemed to represent a high pretest probability for...
colorectal cancer such as rectal bleeding; ‘possible’ diagnostic if the only documented reasons were non-specific medical conditions such as diarrhoea or abdominal pain; or ‘high-risk’ screening, and thus excluded, if the test was performed for screening and the patient had IBD or a strong family history.

Sigmoidoscopies were similarly defined. For FOBTs, tests recorded as performed for screening or performed at home, done in the context of preventive care visit, because of patient preference, or if no specific reason was recorded, were classified as screening.

An adjudication panel (CAD, DAC, MG and RHF) reviewed all available information of patients with colonoscopies that were classified as surveillance, unknown or assigned differing indications across data sources by the computer algorithm. Three panellists independently assigned an indication for tests in each selected patient using a standardised approach. Disagreements were resolved through majority rule or moderated discussions.13 31

Covariates
Patients’ birthdate, sex, race/ethnicity (categorised as non-Hispanic white, non-Hispanic black, Hispanic, Asian/Pacific Islander or other) and health plan enrolment information were obtained from administrative databases. Our socioeconomic status indicator was the percentage of people ≥25 years with at least a high school diploma in a census tract using 2000 decennial census data.32 33

The number of outpatient primary care medical encounters, defined as visits with a family medicine, internal medicine, geriatric or obstetrics/gynaecology specialist, was used as an indicator of health-seeking behaviour; this was enumerated in the 5-year period excluding the 90-day period prior to the reference date and categorised as 0, 1, 2 or ≥3 visits. The Charlson comorbidity index,34 categorised as 0, 1 or ≥2, was used as an indicator of wellness to undergo screening; the score was ascertained from electronic data in the fourth and fifth calendar years prior to the reference date. Family history of colorectal cancer was collected during chart audit, ignoring information recorded in the 30 days before the reference date to minimise information bias, and created a dichotomous variable for such a history that did not meet the exclusion criteria. Screening colonoscopies were deemed inadequate/low quality if the procedure failed to reach the caecum and/or had poor bowel preparation and a subsequent completed endoscopy was not performed.35 36

Figure 1  Flow diagram for the study. Note: *controls were matched to cases on sex, birthdate, health plan enrolment duration and medical service area within each health system. The reference date was the date of the case patient’s colorectal adenocarcinoma. †Each patient dying from colorectal cancer was matched to eight controls with the intent of performing chart audits on the cases and two of the randomly selected controls. CRC, colorectal adenocarcinoma.
Statistical analysis
We estimated adjusted ORs (aOR) and 95% CIs for the association between receipt of screening colonoscopy during the observation period and the risk of any colorectal cancer death, and separately for right-colon and left-colon/rectum cancer deaths, using conditional logistic regression. We also estimated the effects of screening sigmoidoscopy in the same models as colonoscopy. Incidence-density matching generates a representative sample of the historical cohort, and because colorectal cancer mortality is a rare event, we interpreted the ORs as reasonable approximations of relative risks. The multivariate analyses were adjusted for race/ethnicity, family history of colorectal cancer, socioeconomic status indicator, comorbidity score, number of primary care encounters and screening FOBT exposure. We explored unconditional models adjusting for matching variables in all those eligible including unmatched patients (1759 cases and 3633 controls, see figure 1), as previously described and the results were similar.

Screening was defined by exposure to a definite-screening or probable-screening test. People receiving colonoscopy for an abnormal screening sigmoidoscopy were classified as only having received screening with sigmoidoscopy. Thus, the comparison group in all analyses was patients who had not received any screening endoscopy. We used an indicator in the model for the effects of screening sigmoidoscopy in the same models as colonoscopy. Incidence-density matching generates a representative sample of the historical cohort, and because colorectal cancer mortality is a rare event, we interpreted the ORs as reasonable approximations of relative risks. The multivariate analyses were adjusted for race/ethnicity, family history of colorectal cancer, socioeconomic status indicator, comorbidity score, number of primary care encounters and screening FOBT exposure. We explored unconditional models adjusting for matching variables in all those eligible including unmatched patients (1759 cases and 3633 controls, see figure 1), as previously described and the results were similar.

In sensitivity analyses, we restricted the exposure definition to definite-screening only and we recoded probable-screening as diagnostic. We also assessed the sensitivity of our results to restricting the analysis to patients diagnosed with cancer before age 85 years, excluding persons screened by screening FOBT, excluding persons screened by FOBT or sigmoidoscopy, restricting screening exposure to only ‘high-quality’ colonoscopies, and retaining and alternately coding individuals screened by both colonoscopy and sigmoidoscopy as either screening only by sigmoidoscopy or only by screening colonoscopy. All analyses were performed using Stata Statistical Software: Release V14.1 (StataCorp. 2015. College Station, Texas, USA: StataCorp LP).

RESULTS

Patient characteristics
We identified a total of 3585 potential cases from a historical cohort of 1 877 740 people during the study period and audited charts of 1845 potentially case patients who met eligibility criteria and 3778 matched controls (figure 1). During chart audits, we excluded 86 case patients and 145 control patients who did not meet study criteria. Of the eligible 1759 cases and 3633 controls, 33.7% (n=1817) had colonoscopy including 180 for screening, 40.1% (n=2165) had sigmoidoscopy including 1474 for screening (see online supplementary table S1) and 43.4% had at least one prior screening FOBT.

Those excluded from the primary analysis are shown in figure 1. Of the 1747 cases and 3460 matched controls considered in our primary analyses, about half were female, and the majority was non-Hispanic white, had ≥10 years of health plan enrolment and had no significant comorbid illnesses. There was a higher proportion of non-Hispanic blacks, persons of low-socioeconomic status and high comorbidity score in case patients than in control patients (all p values <0.01) (table 1).

Association between screening colonoscopy and colorectal cancer mortality
In our sample, 24 (1.4%) cases and 120 (3.5%) controls had screening colonoscopy during the observation period. Compared with patients who did not receive endoscopic screening, those who received screening colonoscopy had a 67% lower risk of dying from any colorectal cancer (aOR=0.33; CI 0.21 to 0.52) (table 2). For right-colon cancers, 13 (2%) patients who died from colorectal cancer had received screening colonoscopy

---

**Table 1** Demographic and clinical characteristics of patients who died from colorectal cancer and matched controls

<table>
<thead>
<tr>
<th>Characteristics, n (%)</th>
<th>Cases (n=1747)</th>
<th>Controls (n=3460)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Used for case-control matching</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis, years*</td>
<td>50–54</td>
<td>23 (1.3)</td>
</tr>
<tr>
<td></td>
<td>55–64</td>
<td>570 (32.6)</td>
</tr>
<tr>
<td></td>
<td>65–74</td>
<td>504 (28.8)</td>
</tr>
<tr>
<td></td>
<td>75–84</td>
<td>556 (31.8)</td>
</tr>
<tr>
<td></td>
<td>85–89</td>
<td>94 (5.4)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>883 (50.5)</td>
</tr>
<tr>
<td></td>
<td>Study sites</td>
<td></td>
</tr>
<tr>
<td></td>
<td>KPNC</td>
<td>1443 (82.6)</td>
</tr>
<tr>
<td></td>
<td>KPSC</td>
<td>304 (17.4)</td>
</tr>
<tr>
<td></td>
<td>Length of enrolment with health plan before reference date, years</td>
<td>5.0–7.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.5–9.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥10</td>
</tr>
<tr>
<td><strong>Characteristics not used for matching</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race ethnicity</td>
<td>Non-Hispanic white</td>
<td>1170 (67.0)</td>
</tr>
<tr>
<td></td>
<td>Non-Hispanic black</td>
<td>208 (11.9)</td>
</tr>
<tr>
<td></td>
<td>Hispanic</td>
<td>164 (9.4)</td>
</tr>
<tr>
<td></td>
<td>Asian/Pacific Islander</td>
<td>156 (8.9)</td>
</tr>
<tr>
<td></td>
<td>Other/unknown</td>
<td>49 (2.8)</td>
</tr>
<tr>
<td>Per cent with at least a high school diploma, quartiles†</td>
<td>1</td>
<td>374 (21.4)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>419 (24.0)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>435 (24.9)</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>482 (27.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>37 (2.1)</td>
<td>59 (1.7)</td>
</tr>
<tr>
<td>Family history (chart audit)‡</td>
<td>115 (6.6)</td>
<td>202 (5.8)</td>
</tr>
<tr>
<td>Primary care outpatient visits§</td>
<td>0</td>
<td>83 (4.8)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>45 (2.6)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>96 (5.5)</td>
</tr>
<tr>
<td></td>
<td>3+</td>
<td>1523 (87.2)</td>
</tr>
<tr>
<td>Charlson score at beginning of observation window</td>
<td>0</td>
<td>1184 (67.8)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>293 (16.8)</td>
</tr>
<tr>
<td></td>
<td>2+</td>
<td>268 (15.3)</td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (0.1)</td>
<td>4 (0.1)</td>
</tr>
<tr>
<td>Screening sigmoidoscopy</td>
<td>365 (20.9)</td>
<td>1030 (29.8)</td>
</tr>
<tr>
<td>Screening faecal occult blood test</td>
<td>702 (40.2)</td>
<td>1542 (44.6)</td>
</tr>
</tbody>
</table>

*The age at time of diagnosis, the date used to assess exposure and covariate information is shown.
†Data were obtained from the 2000 US Census data at the tract level.
‡Patients for whom the family history of colorectal cancer documented during the observation period did not meet the exclusion criteria. The exclusion was based on a history of colorectal cancer in one or more first-degree relatives before age 50 or in two or more second-degree relatives at any age, or other familial colorectal cancer syndromes.
§Defined based on outpatient clinical visits to family practice, gerontology/geriatrics, internal medicine, obstetrics/gynaecology and “primary care” clinics.
compared with 61 (5.0%) control patients, corresponding to a 65% reduction in the risk of dying from right-colon cancer in those who had received screening colonoscopy as compared with those with no endoscopic screening (aOR=0.35; CI 0.18 to 0.65). We also examined the effect of screening and the risk of death from left-colon/rectum cancers. For this analysis, nine case patients (1.3%) had received screening colonoscopy compared with 56 (4.9%) controls, corresponding to a 75% lower risk for left-colon/rectal cancer deaths (aOR=0.25; CI 0.12 to 0.53). The difference in the size of the associations between the left and right colons was not statistically significant (p value=0.51). These results were not substantively different from those from the bivariate models (table 2). Analyses restricted to patients diagnosed before age 85 years found almost identical results (figure 2). Results were also similar to the primary analysis after excluding patients ever screened with either FOBT or sigmoidoscopy (overall: aOR=0.37, CI 0.16 to 0.84, right colon: aOR=0.36, CI 0.11 to 1.12, and left colon: aOR=0.26, CI 0.06 to 1.02, see table 3), but less precise because of small sample sizes.

In analyses of colonoscopies classified by indication as definite screening, the aOR was 0.25 (CI 0.15 to 0.44) for any colorectal cancer death, 0.37 (CI 0.19 to 0.72) for right-colon cancer death and 0.07 (CI 0.02 to 0.28) for left-colon/rectal cancer death. About 3.5% of screening colonoscopies were considered ‘low-quality’ with no differences in quality between cases and controls. Analyses restricted to ‘high-quality’ screening colonoscopies yielded adjusted risk estimates similar to the primary analysis: the aORs were 0.31 (CI 0.19 to 0.50) for any colorectal cancer death, 0.31 (CI 0.16 to 0.60) for right-colon cancer death and 0.25 (CI 0.12 to 0.54) for left-colon/rectum cancer death. Results were also stable to exclusion of patients classified as exposed to tests with surveillance or unknown indication (data are not shown). Our results were also stable to the exclusion of patients with missing socioeconomic status or race/ethnicity data (data are not shown).

In the sigmoidoscopy analysis, 365 cases (20.9%) and 1030 (29.8%) controls were exposed during the observation period (table 2). The adjusted aORs for the association between receipt of screening sigmoidoscopy and colorectal cancer mortality risk were 0.64 (CI 0.55 to 0.74) overall, 0.75 (CI 0.61 to 0.92) for right-colon cancer deaths and 0.51 (CI 0.41 to 0.65) for the left colon. We also performed analyses retaining patients excluded from the primary analysis because of receiving screening by both colonoscopy and sigmoidoscopy, and classifying them alternately as screening sigmoidoscopy or screening colonoscopy. This did not change our findings (figure 2).

**DISCUSSION**

In this study, we found that receipt of screening colonoscopy, compared with no endoscopic screening, was associated with a 67% lower risk of death from colorectal cancer overall, a 65% lower risk of death from right-colon cancer and a 75% lower risk from left-colon/rectum cancer. The results were similar for analyses restricted to those meeting very strict criteria for screening, high-quality colonoscopies or after excluding patients ever screened with FOBT. The estimate for association of screening colonoscopy with risk of death from cancer in the right colon was smaller than the reduction in the left colon/rectum, which is consistent with findings from other published studies.16–17 21 24 However, the magnitude of the difference observed in our study was relatively small and was not

---

**Table 2  Association between receipt of screening endoscopy and colorectal adenocarcinoma death risk**

<table>
<thead>
<tr>
<th>Screening colonoscopy status according to colon location</th>
<th>Case patients, n=1747</th>
<th>Matched control patients, n=3460</th>
<th>Estimated relative risks (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bivariate model</td>
</tr>
<tr>
<td>All locations in the colon/rectum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No screening endoscopy</td>
<td>1358</td>
<td>2310</td>
<td>1.00</td>
</tr>
<tr>
<td>Screening colonoscopy</td>
<td>24</td>
<td>120</td>
<td>0.33 (0.21 to 0.52)</td>
</tr>
<tr>
<td>Screening sigmoidoscopy</td>
<td>365</td>
<td>1030</td>
<td>0.60 (0.52 to 0.69)</td>
</tr>
<tr>
<td>Right colon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No screening endoscopy</td>
<td>649</td>
<td>1151</td>
<td>1.00</td>
</tr>
<tr>
<td>Screening colonoscopy</td>
<td>13</td>
<td>61</td>
<td>0.37 (0.20 to 0.68)</td>
</tr>
<tr>
<td>Screening sigmoidoscopy</td>
<td>218</td>
<td>535</td>
<td>0.72 (0.59 to 0.87)</td>
</tr>
<tr>
<td>Left colon/rectum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No screening endoscopy</td>
<td>669</td>
<td>1092</td>
<td>1.00</td>
</tr>
<tr>
<td>Screening colonoscopy</td>
<td>9</td>
<td>56</td>
<td>0.25 (0.12 to 0.50)</td>
</tr>
<tr>
<td>Screening sigmoidoscopy</td>
<td>138</td>
<td>468</td>
<td>0.48 (0.38 to 0.59)</td>
</tr>
</tbody>
</table>

*The multivariate model adjusted for race/ethnicity, family history, percentage of people 25+ years in the census tract with at least a high-school diploma, Charlson comorbidity score and number of primary care visits, as well as an indicator faecal occult blood testing. The estimates were obtained from conditional regression models.
The association between colonoscopy and colorectal cancer death has been reported separately for right-colon and left-colon cancers in four studies, but each had potential methodological weaknesses. However, the study relied exclusively on administrative data, which lack the details needed to control for confounding and to distinguish tests done for routine screening from those performed for diagnostic purposes such as abdominal masses, or as follow-up to a positive sigmoidoscopy or FOBT. It was thus unable to distinguish screening from diagnostic tests, and instead restricted the analyses to tests received more than 6 months before the diagnosis date, which are expected to be generally negative for cancer. Thus, that study described the degree to which any negative colonoscopy predicts risk of fatal colorectal cancer rather than the effectiveness of screening colonoscopy in reducing the risk of death from colorectal cancer.

An analysis of the Nurses’ Health Study and the Health Professionals Follow-up Study cohorts found a lower risk of colorectal cancer deaths in participants who reported a prior screening colonoscopy: 53% lower for the right colon/rectum and 82% lower for the left colon. The screening indication in that study was self-reported and not confirmed by medical records. A previous case–control study by our group in a different population also found protective associations for colonoscopy in both the right and left colon for late-stage cancer. Thus, the magnitude of screening effect on mortality cannot be directly inferred from that study because treatments may be effective regardless of stage, particularly with recent improvements in therapy for clinically advanced disease.

Our study also has limitations, mainly the possibility that the results could have partly been due to residual confounding. However, we were able to account for the main potential confounders by exclusion, matching, stratification and adjustment in statistical analysis. Further, our previous analysis found that the magnitude of bias from potentially confounding variables that we were unable to measure, such as lifestyle factors, is small and unlikely to substantially affect our results. Having <10 years of enrolment history (35% of patients in our study) may result in incomplete capture of colonoscopy use. To minimise potential differential ascertainment of exposure, we matched cases and controls on enrolment history. However, screening exposures in cases tend to occur close to the diagnosis date but are more evenly distributed in controls and thus may bias the results towards the null, further supporting our findings.

A particular strength of our study was its setting within large community-based integrated healthcare systems with stable membership and extensive coded and free-text clinical data. Thus, we were able to define a historic cohort of members and, from it, sample average-risk patients to provide estimates that are generalisable to the source population. Also, we could reliably assign indications for colonoscopies and specifically define the subsets that were for screening using clinical information from several sources, a pretested algorithm and adjudication by clinicians. Although this approach resulted in a lower exposure rate than has been reported in this population, a greater threat to validity would arise from classifying diagnostic tests as screening than the converse. Also, clinical databases were linked with detailed information in cancer and death registries.

As in all clinical settings, screening colonoscopy took place in the context of other colorectal cancer screening tests that might confound or modify its effects. During the period of our study, the health systems in this study relied primarily on guaiac-FOBT and sigmoidoscopy before implementing system-wide screening outreach programmes with faecal immunochemical tests. We were able to assess for confounding effects of other screening tests including when both sigmoidoscopy and colonoscopy were used. We found no strong evidence that screening FOBT confounded our estimates. Using the same models as were used for estimating colonoscopy’s effectiveness, we also found that receipt of screening sigmoidoscopy was associated with a reduced risk of any colorectal cancer death by 36%. This estimate was similar to results from randomised trials (risk ratios: 0.577 and 0.626) and thus supports the validity of our research design and analyses.

Clinical practice guidelines have included colonoscopy among colorectal cancer screening options in average-risk people since 1997, based largely on indirect evidence of effectiveness such as biological plausibility related to the adenoma–carcinoma sequence and generalisations from the established effectiveness of sigmoidoscopy and its use as a follow-up test within FOBT trials. The use of colonoscopy has also been supported by results of a cohort study of patients who had undergone polypectomy, and modelling studies. However, conflicting findings of previous studies have left uncertainties about screening colonoscopy’s effectiveness, particularly in the right colon.

### Table 3: Association between receipt of screening endoscopy and colorectal adenocarcinoma death risk; excluding persons who had undergone faecal occult blood or sigmoidoscopy screening

<table>
<thead>
<tr>
<th>Screening colonoscopy status according to colon location</th>
<th>Case patients, n=836</th>
<th>Matched control patients, n=1453</th>
<th>Estimated relative risks (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All locations in the colon/rectum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No screening colonoscopy</td>
<td>822</td>
<td>1453</td>
<td>1.00</td>
</tr>
<tr>
<td>Screening colonoscopy</td>
<td>14</td>
<td>66</td>
<td>0.39 (0.18 to 0.84)</td>
</tr>
<tr>
<td>Right colon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No screening colonoscopy</td>
<td>370</td>
<td>647</td>
<td>1.00</td>
</tr>
<tr>
<td>Screening colonoscopy</td>
<td>6</td>
<td>34</td>
<td>0.42 (0.15 to 1.17)</td>
</tr>
<tr>
<td>Left colon/rectum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No screening colonoscopy</td>
<td>423</td>
<td>655</td>
<td>1.00</td>
</tr>
<tr>
<td>Screening colonoscopy</td>
<td>7</td>
<td>28</td>
<td>0.29 (0.08 to 1.04)</td>
</tr>
</tbody>
</table>

*Multivariate conditional logistic regression models were adjusted for race/ethnicity, family history, percentage of people 25+ years in the census tract with at least a high-school diploma, Charlson score and number of primary care visits. Analysis excluded all people exposure to screening with faecal occult blood test or sigmoidoscopy.
have suggested, then the added inconvenience, risk and cost associated with screening colonoscopy use for average-risk people, compared with sigmoidoscopy, would be difficult to justify.

The current study found a strong association between receipt of screening colonoscopy and a reduced risk of death from colorectal adenocarcinomas arising in either the right colon or left colon/rectum. In contrast to recent recommendations against colonoscopy, which cited a lack of high-quality evidence, the current study from a well-defined cohort supports colonoscopy as an effective screening test for reducing mortality risk from both left and right-sided colon cancers, and should help allay concerns that it could be substantially less effective in the right than the left colon/rectum or less effective in real-world community-based populations. The study’s methodological rigour and setting are nearly identical to those from a prior analysis, which supported colon/rectum or less effective in real-world community-based populations. The randomised trials of screening colonoscopy, currently under way, will add to this body of knowledge but may be underpowered to separately evaluate effects in the right and left colon.

Author affiliations
1 Department of Family Medicine and Community Health, The Abramson Cancer Center, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2 Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
3 Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA
4 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
5 Department of Epidemiology, Emory University, Atlanta, Georgia, USA
6 Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
7 Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
8 Department of Epidemiology, University of Washington, Seattle, Washington, USA
9 Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA

Twitter Follow Shivan Mehta at @shivan_mehta

Contributors CAD, DAC, VPO, CDJ, AGZ, MG, TAB, JS, VPD-R, TRL, NSW and RHF conceived of the study and participated in its design and coordination. CAD conducted the data analysis, interpreted the findings and drafted the original manuscript. DAC, VPO, AGZ, RJM, SMB, NSW and RHF contributed to interpretation of the findings and writing of the manuscript. WKZ participated in data collection and reviewing. All authors read and approved the final manuscript.

Funding This study was supported by an award (number U01CA151736) from the United States National Cancer Institute of the National Institutes of Health. The views expressed here are those of the authors only and do not represent any official position of the National Cancer Institute or National Institutes of Health.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Additional summary tables and sensitivity analyses are available upon request from the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
20 Dominitz JA, Robertson DJ. Coloscopy versus fecal immunochemical test in reducing mortality from colorectal cancer (CONFIRM). 2012;NCT01239082.
21 Uppsala University Hospital. Colonoscopy and FIT as colorectal cancer screening test in the average risk population. ClinicalTrials.gov 2014;NCT02078804.
Endoscopy


39 Weiss NS. Commentary: case-control studies of screening for colorectal cancer: tailoring the design and analysis to the specific research question. Epidemiology 2013;24:894–7.


